Researchers reported development of CAR T cells engineered to target antigens associated with HIV-linked B cell malignancies, offering a tailored cell therapy strategy for a distinct subset of hematologic cancers. The approach leverages viral-associated markers on malignant B cells to increase tumor specificity and reduce off-tumor toxicity risks. Early preclinical results indicate robust on‑target activity; translation to clinical testing will hinge on safety profiling and manufacturability, but the work highlights the continuing diversification of CAR platforms beyond classic lineage antigens.